logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
    • Investors
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us
glycotest_logo
logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
    • Investors
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us

Glycotest Update

June 26, 2017
-
News
-
No comments
-
Posted by Webmaster

London, UK – June 26th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, provides an update on the series A fundraising being undertaken by its portfolio company Glycotest, a US-based diagnostics company, as outlined in the Circular issued to shareholders following the Company’s placing and subscription of new shares on 26 May 2017 (the “Circular”).

The Company continues to anticipate closing the Series A round within the second half of 2017, but does not now expect to sign the relevant documentation by the end of June 2017, as was previously stated as the Company’s aim in the Circular.

As at 31 December 2016 the NetScientific had invested £2.4 million in Glycotest. The Company expects that the delay will lead to an increase in its £0.5m expected spend in Glycotest in 2017, as stated in the Circular, but with overall spend remaining under £1.0m in 2017.

# # #

For more information, please contact:

NetScientific
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800

Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton

Tel: +44 (0)20 3709 5700
netscientific@consilium-comms.com
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600

About NetScientific

NetScientific is an IP commercialisation group focused on healthcare with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

About Glycotest

Glycotest is a US based diagnostics company, developing biomarkers for clinical laboratory
services used in the diagnosis of liver cancers and fibrosis-cirrhosis, which the Directors
believe represents a $1 billion market opportunity. Its blood-based biomarkers take advantage
of sugar-related disease signals and the company has issued patents to over 50 serum proteins
with sugar structures that are altered in liver disease. The biomarkers are being developed into
tests and test panels intended for the surveillance of patients with serious liver disease.

← PREVIOUS POST
Glycotest™ Intellectual Property Portfolio Expanded by United Sates, European and Australian Patents
NEXT POST →
Glycotest Innovator Joins the Medical University of South Carolina as the New SmartState Endowed Chair of Proteomic Biomarkers

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Related News

Other posts that you should not miss.

Six new patents protecting Glycotest’s HCC Panel test have been issued or allowed in the United States, Europe, China, Taiwan, Japan, and Mexico.

March 1, 2023
-
News
Read More →
Posted by glycotest
1 MIN READ

Glycotest’s Patent Portfolio Covering Detection of Serious Liver Disease Expanded by Grant of European Patent.

January 13, 2021
-
News
Read More →
Posted by glycotest
1 MIN READ

More than 50 Glycotest Fucosylated Biomarkers Protected through Grant of New US Patent.

November 3, 2020
-
News
Read More →
Posted by glycotest
1 MIN READ

GET IN TOUCH

Give Us A Call

+1 484-431-3483

Send Us A Message

info@glycotest.com

Copyright© All Rights Reserved
Website Designed & Developed by Jason and Company
Glycotest Update | Glycotest Diagnostics